Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2020

11.11.2019 | short review

Evidence-based follow-up in renal cell carcinoma

verfasst von: MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as well as surveillance after local ablative therapy. The recommendations and differences of major guidelines are outlined as well. A risk based approach is advocated taking into account both tumor and patient specific characteristics.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
2.
Zurück zum Zitat Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, et al. Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival. Clin Genitourin Cancer. 2019;17(2):132–8. PubMedCrossRef Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, et al. Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival. Clin Genitourin Cancer. 2019;17(2):132–8. PubMedCrossRef
3.
Zurück zum Zitat Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol. 2018;36(1):11.e1–11.e6. CrossRef Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol. 2018;36(1):11.e1–11.e6. CrossRef
4.
Zurück zum Zitat Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51. PubMedCrossRef Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51. PubMedCrossRef
5.
Zurück zum Zitat Beisland C, Guðbrandsdottir G, Reisæter LAR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol. 2016;34(8):1087–99. PubMedCrossRef Beisland C, Guðbrandsdottir G, Reisæter LAR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol. 2016;34(8):1087–99. PubMedCrossRef
6.
Zurück zum Zitat Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174(2):466–72. discussion 472; quiz 801. PubMedCrossRef Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174(2):466–72. discussion 472; quiz 801. PubMedCrossRef
7.
Zurück zum Zitat Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63. discussion 1763. PubMedCrossRef Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63. discussion 1763. PubMedCrossRef
8.
Zurück zum Zitat Patard J‑J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the university of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22. PubMedCrossRef Patard J‑J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the university of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22. PubMedCrossRef
9.
Zurück zum Zitat Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7. PubMedCrossRef Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7. PubMedCrossRef
10.
Zurück zum Zitat Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101–6. PubMedCrossRef Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101–6. PubMedCrossRef
11.
Zurück zum Zitat Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol. 2013;64(3):472–7. PubMedCrossRef Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol. 2013;64(3):472–7. PubMedCrossRef
12.
Zurück zum Zitat Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32(36):4059–65. PubMedPubMedCentralCrossRef Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32(36):4059–65. PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol. 2015;33(35):4151–7. PubMedCrossRef Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol. 2015;33(35):4151–7. PubMedCrossRef
14.
Zurück zum Zitat Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European Multicentre database (RECUR). Eur Urol. 2019;75(2):261–4. PubMedCrossRef Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European Multicentre database (RECUR). Eur Urol. 2019;75(2):261–4. PubMedCrossRef
15.
Zurück zum Zitat Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, et al. The usefulness of chest X‑rays for T1a renal cell carcinoma surveillance. J Urol. 2016;196(2):321–6. PubMedCrossRef Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, et al. The usefulness of chest X‑rays for T1a renal cell carcinoma surveillance. J Urol. 2016;196(2):321–6. PubMedCrossRef
16.
Zurück zum Zitat Chow AK, Kahan AN, Hwang T, Coogan CL, Latchamsetty KC. Should we separate the pulmonary surveillance protocol for postsurgical T1a and T1b renal cell carcinoma? A multicenter database analysis. Urology. 2018;122:127–32. PubMedCrossRef Chow AK, Kahan AN, Hwang T, Coogan CL, Latchamsetty KC. Should we separate the pulmonary surveillance protocol for postsurgical T1a and T1b renal cell carcinoma? A multicenter database analysis. Urology. 2018;122:127–32. PubMedCrossRef
17.
Zurück zum Zitat Doornweerd BHJ, de Jong IJ, Bergman LM, Ananias HJK. Chest X‑ray in the follow-up of renal cell carcinoma. World J Urol. 2014;32(4):1015–9. PubMed Doornweerd BHJ, de Jong IJ, Bergman LM, Ananias HJK. Chest X‑ray in the follow-up of renal cell carcinoma. World J Urol. 2014;32(4):1015–9. PubMed
18.
Zurück zum Zitat Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand J Urol. 2019;53(1):14–20. PubMedCrossRef Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand J Urol. 2019;53(1):14–20. PubMedCrossRef
19.
Zurück zum Zitat Platzek I, Zastrow S, Deppe P‑E, Grimm M‑O, Wirth M, Laniado M, et al. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol. 2010;51(5):581–9. PubMedCrossRef Platzek I, Zastrow S, Deppe P‑E, Grimm M‑O, Wirth M, Laniado M, et al. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol. 2010;51(5):581–9. PubMedCrossRef
20.
Zurück zum Zitat Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38(2):156–63. PubMedCrossRef Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38(2):156–63. PubMedCrossRef
21.
Zurück zum Zitat Gofrit ON, Orevi M. Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography. J Urol. 2016;196(3):648–57. PubMedCrossRef Gofrit ON, Orevi M. Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography. J Urol. 2016;196(3):648–57. PubMedCrossRef
22.
23.
Zurück zum Zitat Shvarts O, Lam JS, Kim HL, Han K, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004;172(3):867–70. PubMedCrossRef Shvarts O, Lam JS, Kim HL, Han K, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004;172(3):867–70. PubMedCrossRef
24.
Zurück zum Zitat Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179(4):1227–33. discussion 1233–1234. PubMedCrossRef Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179(4):1227–33. discussion 1233–1234. PubMedCrossRef
25.
Zurück zum Zitat Iannuccilli J, Grand D, Dupuy D, Mayo-Smith W. Percutaneous ablation for small renal masses-imaging follow-up. Semin intervent Radiol. 2014;31(1):50–63. PubMedPubMedCentralCrossRef Iannuccilli J, Grand D, Dupuy D, Mayo-Smith W. Percutaneous ablation for small renal masses-imaging follow-up. Semin intervent Radiol. 2014;31(1):50–63. PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176(5):1973–7. PubMedCrossRef Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176(5):1973–7. PubMedCrossRef
27.
Zurück zum Zitat Patel U, Sokhi H. Imaging in the follow-up of renal cell carcinoma. AJR Am J Roentgenol. 2012;198(6):1266–76. PubMedCrossRef Patel U, Sokhi H. Imaging in the follow-up of renal cell carcinoma. AJR Am J Roentgenol. 2012;198(6):1266–76. PubMedCrossRef
28.
Zurück zum Zitat Thumar AB, Trabulsi EJ, Lallas CD, Brown DB. Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol. 2010;21(8 Suppl):S233–41. PubMedCrossRef Thumar AB, Trabulsi EJ, Lallas CD, Brown DB. Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol. 2010;21(8 Suppl):S233–41. PubMedCrossRef
29.
Zurück zum Zitat Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. PubMedCrossRef Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. PubMedCrossRef
30.
Zurück zum Zitat Motzer RJ, Jonasch E, Agarwal N, National Comprehensive Cancer Network. Kidney Cancer. 2019;64. Referenced with permission from the NCCN Guidelines® for Kidney Cancer V.2.2020 © National Comprehensive Cancer Network. 2019. www.​NCCN.​org. Accessed 28 June 2019. Motzer RJ, Jonasch E, Agarwal N, National Comprehensive Cancer Network. Kidney Cancer. 2019;64. Referenced with permission from the NCCN Guidelines® for Kidney Cancer V.2.2020 © National Comprehensive Cancer Network. 2019. www.​NCCN.​org. Accessed 28 June 2019.
31.
Zurück zum Zitat Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190:407–16. PubMedCrossRef Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190:407–16. PubMedCrossRef
32.
Zurück zum Zitat Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20. PubMedCrossRef Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20. PubMedCrossRef
33.
Zurück zum Zitat Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006;8(1):1–7. PubMedPubMedCentral Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006;8(1):1–7. PubMedPubMedCentral
34.
Zurück zum Zitat Williamson TJ, Pearson JR, Ischia J, Bolton DM, Lawrentschuk N. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016;117(4):555–62. PubMedCrossRef Williamson TJ, Pearson JR, Ischia J, Bolton DM, Lawrentschuk N. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016;117(4):555–62. PubMedCrossRef
Metadaten
Titel
Evidence-based follow-up in renal cell carcinoma
verfasst von
MD Karl Mayrhofer
MD, MBA Dora Niedersüß-Beke
Publikationsdatum
11.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00540-9